SCM
Superstring Capital Management Portfolio holdings
AUM
$80.3M
This Quarter Return
-8.11%
1 Year Return
+68.23%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$114M
AUM Growth
+$114M
(+1.8%)
Cap. Flow
+$18.5M
Cap. Flow
% of AUM
16.28%
Top 10 Holdings %
Top 10 Hldgs %
68.83%
Holding
46
New
19
Increased
9
Reduced
9
Closed
8
Top Buys
| 1 |
Cogent Biosciences
COGT
|
$7.1M |
| 2 |
IDEAYA Biosciences
IDYA
|
$5.84M |
| 3 |
Oric Pharmaceuticals
ORIC
|
$5.09M |
| 4 |
Terns Pharmaceuticals
TERN
|
$3.72M |
| 5 |
UroGen Pharma
URGN
|
$3.21M |
Top Sells
| 1 |
Zai Lab
ZLAB
|
$5.85M |
| 2 |
Cytokinetics
CYTK
|
$4.06M |
| 3 |
Capricor Therapeutics
CAPR
|
$3.89M |
| 4 |
89bio
ETNB
|
$3.61M |
| 5 |
Nkarta
NKTX
|
$3.35M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
89bio
ETNB
$1.37B
| $1.04M | 0.9% |
132,982
-462,221
| -78% | -$3.61M |
|
|
ZBIO
27
Zenas BioPharma, Inc. Common Stock
ZBIO
$722M
| $914K | 0.79% |
111,605
| – | – |
|
|
28
Capricor Therapeutics
CAPR
$287M
| $762K | 0.66% |
55,229
-282,118
| -84% | -$3.89M |
|
29
Kyverna Therapeutics
KYTX
$161M
| $681K | 0.59% |
+182,177
| New | +$681K |
|
30
Rezolute
RZLT
$630M
| $604K | 0.52% |
+123,184
| New | +$604K |
|
31
Century Therapeutics
IPSC
$40.4M
| $468K | 0.4% |
+462,963
| New | +$468K |
|
32
Zura Bio
ZURA
$132M
| $467K | 0.4% |
186,943
+30,317
| +19% | +$75.8K |
|
33
EyePoint Pharmaceuticals
EYPT
$827M
| $368K | 0.32% |
+49,375
| New | +$368K |
|
34
Axsome Therapeutics
AXSM
$6.09B
| $361K | 0.31% |
+4,268
| New | +$361K |
|
35
Madrigal Pharmaceuticals
MDGL
$9.7B
| $348K | 0.3% |
+1,129
| New | +$348K |
|
36
Lexeo Therapeutics
LXEO
$266M
| $346K | 0.3% |
+52,616
| New | +$346K |
|
|
CLYM
37
Climb Bio, Inc. Common Stock
CLYM
$165M
| $177K | 0.15% |
98,160
+64,336
| +190% | +$116K |
|
|
LSB
38
LakeShore Biopharma
LSB
$34.9M
| $106K | 0.09% |
30,792
-277,128
| -90% | – |
|
|
39
Nkarta
NKTX
$149M
| – | – |
-740,294
| Closed | -$3.35M |
|
40
Spyre Therapeutics
SYRE
$1.02B
| – | – |
-37,287
| Closed | -$1.1M |
|
41
Tourmaline Bio
TRML
$645M
| – | – |
-29,104
| Closed | -$748K |
|
42
Allogene Therapeutics
ALLO
$249M
| – | – |
-478,115
| Closed | -$1.34M |
|
43
Biomea Fusion
BMEA
$114M
| – | – |
-83,554
| Closed | -$844K |
|
44
Cullinan Oncology
CGEM
$456M
| – | – |
-20,840
| Closed | -$349K |
|
45
Corbus Pharmaceuticals
CRBP
$121M
| – | – |
-25,401
| Closed | -$524K |
|
46
Immunovant
IMVT
$2.91B
| – | – |
-12,447
| Closed | -$355K |
|